These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30251117)

  • 1. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
    Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
    Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
    Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
    Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.
    Fu J; Rodova M; Nanta R; Meeker D; Van Veldhuizen PJ; Srivastava RK; Shankar S
    Neuro Oncol; 2013 Jun; 15(6):691-706. PubMed ID: 23482671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
    Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.
    Nanta R; Kumar D; Meeker D; Rodova M; Van Veldhuizen PJ; Shankar S; Srivastava RK
    Oncogenesis; 2013 Apr; 2(4):e42. PubMed ID: 23567619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
    Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
    Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
    Molecules; 2020 May; 25(10):. PubMed ID: 32466169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R; Morchon E; Martinez-Argudo I; Serrano R
    Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis.
    Helmy MW; Ghoneim AI; Katary MA; Elmahdy RK
    Mol Biol Rep; 2020 Mar; 47(3):2217-2230. PubMed ID: 32088816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
    Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
    J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.